This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Viereck, J. et al. Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehaa519 (2020)
Related article
Nakamura, M. & Sadoshima, J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat. Rev. Cardiol. 15, 387–407 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fernández-Ruiz, I. H19 in cardiac hypertrophy. Nat Rev Cardiol 17, 612 (2020). https://doi.org/10.1038/s41569-020-0434-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-020-0434-4
This article is cited by
-
Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects
Nature Reviews Cardiology (2023)
-
Inhibition of lncRNA DANCR Prevents Heart Failure by Ameliorating Cardiac Hypertrophy and Fibrosis Via Regulation of the miR-758-3p/PRG4/Smad Axis
Journal of Cardiovascular Translational Research (2023)